Return to homepagePandemic Pact

Antibody based therapeutic development for coronaviruses

  • Funded by National Health and Medical Research Council (NHMRC)
  • Total publications:0 publications

Grant number: GA276505

Grant search

Key facts

  • Disease

    COVID-19, Severe Acute Respiratory Syndrome (SARS), Middle East respiratory syndrome coronavirus (MERS)

  • Start & end year

    2023
    2026

  • Known Financial Commitments (USD)

    $817,916.8

  • Funder

    National Health and Medical Research Council (NHMRC)

  • Research Location

    Australia

  • Lead Research Institution

    The Walter and Eliza Hall Institute of Medical Research

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Pathogen morphology, shedding & natural history

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

The first human coronavirus was isolated from individuals suffering from the common cold in the 1960’s. Since then, three highly pathogenic human coronaviruses have arisen in the last two decades; SARS in 2002, MERS in 2012 and the devastating COVID-19 pandemic. It is critical we understand how current and emerging coronaviruses infect humans and more importantly, develop therapeutic agents to tackle current disease, resist future SARS-CoV-2 variants and new coronavirus-origin pandemics.